BRAF G466V

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
BRAF G466V	Pan-RAF/MEK Molecular Glue NST-628	Predictive	D	Supports Sensitivity Response	3	submitted	EID13159 In the BRAF G466V-mutant NCI-H1666 model, NST-628 suppressed MAPK signaling without inducing BRAF–CRAF heterodimer formation. NCI-H1666 was also included in a panel of BRAF class II/III-mutant cell li… (full text at CIViC) PMID 38588399 · Ryan et al., 2024 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
BRAF G466V	Cetuximab	Predictive	D	Supports Sensitivity Response	3	rejected	EID12441 Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma1

BRAF G466V

Pan-RAF/MEK Molecular Glue NST-628

Predictive

Supports Sensitivity Response

submitted

EID13159

In the BRAF G466V-mutant NCI-H1666 model, NST-628 suppressed MAPK signaling without inducing BRAF–CRAF heterodimer formation. NCI-H1666 was also included in a panel of BRAF class II/III-mutant cell li… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma2

BRAF G466V

Cetuximab

Predictive

Supports Sensitivity Response

rejected

EID12441

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13967	Pathogenic	no assertion criteria provided	0	Lung adenocarcinoma; Non-small cell lung carcinoma	somatic	2	May 29, 2009	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

13967

Pathogenic

no assertion criteria provided

Lung adenocarcinoma; Non-small cell lung carcinoma

somatic

May 29, 2009

clinvar

Malignant Colorectal Neoplasm3
BRAF G466V	Cetuximab	Predictive	D	Supports Sensitivity Response	3	submitted	EID12437 In the study with a tumour from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumour regression. And in tumour cell… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF G466V	Irinotecan + PanitumumabCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID7552 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF G466V	Vemurafenib	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7553 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells … (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic

Malignant Colorectal Neoplasm3

BRAF G466V

Cetuximab

Predictive

Supports Sensitivity Response

submitted

EID12437

In the study with a tumour from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumour regression. And in tumour cell… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

BRAF G466V

Irinotecan + PanitumumabCombination

Predictive

Supports Sensitivity Response

accepted

EID7552

In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

BRAF G466V

Vemurafenib

Predictive

Does Not Support Sensitivity Response

accepted

EID7553

In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

Malignant Neoplasm4
BRAF G466V	Trametinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12452 Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. NSCLC cell lines H1666 and CAL-12T bearing the BRAF G466V mutation were sensitive with… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF G466V	Vemurafenib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5968 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
NRAS Q61K AND BRAF G466V	Cetuximab	Predictive	D	Supports Resistance	3	submitted	EID12450 Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab as measured by cell growth and RAS-GT… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
NRAS Q61K AND BRAF G466V	Trametinib	Predictive	D	Does Not Support Resistance	3	submitted	EID12451 Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab but not trametinib as measured by cel… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic

Malignant Neoplasm4

BRAF G466V

Trametinib

Predictive

Supports Sensitivity Response

submitted

EID12452

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. NSCLC cell lines H1666 and CAL-12T bearing the BRAF G466V mutation were sensitive with… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

BRAF G466V

Vemurafenib

Predictive

Does Not Support Sensitivity Response

accepted

EID5968

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

civic

NRAS Q61K AND BRAF G466V

Cetuximab

Predictive

Supports Resistance

submitted

EID12450

Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab as measured by cell growth and RAS-GT… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

NRAS Q61K AND BRAF G466V

Trametinib

Predictive

Does Not Support Resistance

submitted

EID12451

Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab but not trametinib as measured by cel… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

Solid Neoplasm1
BRAF G466V	Vemurafenib	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7554 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic

Solid Neoplasm1

BRAF G466V

Vemurafenib

Predictive

Does Not Support Sensitivity Response

accepted

EID7554

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

Evidence by cancer (11 items)

Clinical significance (1)